Zhitong Finance App News, and Platinum Pharmaceutical-B (02142) announced interim results for the six months ended June 30, 2026, with revenue of US$122 million, up 20.9% year on year; profit for the period was US$64.851 million, down 11.16% year on year; basic profit per share.

According to the announcement, total revenue during the reporting period was US$122 million, an increase of 20.9% over US$101 million in the first half of 2025. Molecular licensing and cooperation revenue increased from US$93.7 million to US$113 million, mainly due to continued strategic cooperation with leading global pharmaceutical companies and external licensing and cooperation for innovative products. Meanwhile, revenue from research services and technology licensing fees increased 23.8% from US$7.6 million to US$9.4 million.

In December 2025, we entered into a long-term global strategic cooperation and licensing agreement with Bristol-Myers Squibb to develop a new generation of multi-specific antibodies. In return, if Bristol-Myers Squibb chooses to advance all potential projects, the company will receive a total payment of $90 million, as well as development and commercial milestone payments of up to $1,035 million, as well as tiered royalties.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.